Ultragenyx Pharmaceutical (RARE) Equity Ratio (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Equity Ratio of 0.18 for Q1 2026, down 265.9% year-over-year from 0.11 in Q1 2025, and down 248.72% on a QoQ basis from 0.05 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Equity Ratio data on file, last reported at 0.18 in Q1 2026.
- Quarterly Equity Ratio fell 265.9% year-over-year to 0.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.18 (down 265.9% YoY) and the FY2025 annual result came in at 0.05, down 130.78% from the prior year.
- Equity Ratio eased to 0.18 in Q1 2026 per RARE's latest filing, from 0.05 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.58 in Q1 2022 and bottomed at 0.18 in Q1 2026.
- The 5-year median for Equity Ratio is 0.16 (2023), against an average of 0.17.
- The widest annual swing landed in 2024, when Equity Ratio surged 780.18%; it then sank 265.9% in 2026.
- Tracing RARE's Equity Ratio over 5 years: stood at 0.23 in 2022, then dropped by 19.02% to 0.18 in 2023, then declined by 8.01% to 0.17 in 2024, then plunged by 130.78% to 0.05 in 2025, then tumbled by 248.72% to 0.18 in 2026.
- Per Business Quant, the three latest RARE Equity Ratio figures stand at 0.18 (Q1 2026), 0.05 (Q4 2025), and 0.01 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.73 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.77 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.21 |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.18 |
| Dec 31, 2025 | -0.05 |
| Sep 30, 2025 | 0.01 |
| Jun 30, 2025 | 0.12 |
| Mar 31, 2025 | 0.11 |
| Dec 31, 2024 | 0.17 |
| Sep 30, 2024 | 0.23 |
| Jun 30, 2024 | 0.27 |
| Mar 31, 2024 | 0.11 |
| Dec 31, 2023 | 0.18 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.10 |
| Mar 31, 2023 | 0.16 |
| Dec 31, 2022 | 0.23 |
| Sep 30, 2022 | 0.29 |
| Jun 30, 2022 | 0.51 |
| Mar 31, 2022 | 0.58 |
| Dec 31, 2021 | 0.61 |
| Sep 30, 2021 | 0.63 |
| Jun 30, 2021 | 0.64 |
| Mar 31, 2021 | 0.66 |
| Dec 31, 2020 | 0.66 |
| Sep 30, 2020 | 0.53 |
| Mar 31, 2020 | 0.49 |
| Dec 31, 2019 | 0.58 |
| Sep 30, 2019 | 0.83 |
| Jun 30, 2019 | 0.85 |
| Mar 31, 2019 | 0.88 |
| Dec 31, 2018 | 0.85 |
| Sep 30, 2018 | 0.87 |
| Jun 30, 2018 | 0.87 |
| Mar 31, 2018 | 0.89 |
| Dec 31, 2017 | 0.78 |
| Sep 30, 2017 | 0.84 |
| Jun 30, 2017 | 0.86 |
| Mar 31, 2017 | 0.89 |
| Dec 31, 2016 | 0.88 |
| Sep 30, 2016 | 0.88 |
| Jun 30, 2016 | 0.92 |
| Mar 31, 2016 | 0.00 |
| Dec 31, 2015 | 0.95 |
| Sep 30, 2015 | 0.96 |
| Jun 30, 2015 | 0.93 |
| Mar 31, 2015 | 0.96 |
| Dec 31, 2014 | 0.93 |
| Sep 30, 2014 | 0.94 |
| Jun 30, 2014 | 0.94 |
| Mar 31, 2014 | 0.96 |
| Dec 31, 2013 | -1.25 |